

Objectives

Funding for clinical research comes from the federal government or the private sector. In addition to providing financial resources, some funding groups also provide the investigational agent. They are referred to as the Sponsor and are responsible for the initiation and management of a new agent under the FDA's Investigation New Drug (IND) Application (Title 21 Part 312). This module will review the role of the IND sponsor.

- At the conclusion of this module, you will be able to:
- Define what is meant by a "sponsor"
 List the 4 broad areas of sponsor responsibilities
- Describe the purpose of FDA Form 1571
- · List 5 items that are submitted with an initial IND application



Definition of Sponsor....

- "An individual, company, institution or organization which takes responsibility for the initiation, management, and / or financing of a clinical trial." (ICH)
- "A person who takes responsibility for and initiates a clinical investigation. ... The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator." (CFR)

....Definition of Sponsor

- In general, the sponsor is the commercial manufacturer that has developed a product in which it holds the principal financial interest
- Holds the IND (Investigational New Drug) application and files the NDA / BLA (New Drug Application/Biological Licensing Application)

Sponsors Responsibilities: 4 Broad Areas

- Preclinical / non-clinical
 - Manufacturing
- Clinical
- Post-approval
- May use a CRO (Contract Research Organization)



Preclinical Goals

- Find a product
 - Pharmacological activity - Reasonably safe
- Conduct pre-clinical studies
 - animal pharmacology, toxicology, and carcinogenicity

Preclinical Studies

Purposes of PRECLINICAL studies are to:

- Determine the optimal formulation of the product
- Select an initial safe starting dose for human trials
- Identify potential target organs of toxicity
- Recommend appropriate types of clinical monitoring

Manufacturing **Responsibilities**

Obtain manufacturing information:

- Characterization of the product

- Preliminary stability studies



Clinical Responsibilities

- Submit & maintain Investigational New Drug Application (IND) with FDA
- Conducting Phase 1, 2, 3 Clinical Trials
- Submit New Drug Application (NDA) to FDA for drugs
- Submit Biological License Application (BLA) to FDA for biologics

Investigational New Drug **Application (IND)**

- Sponsor submits to the FDA
- Descriptive notification of intention to conduct clinical studies with an investigational drug or biologic
- Allows for transportation of product • (non-approved drug) across state lines

IND Sections

- FDA Form 1571
- Table of contents Intro statement
- General
- investigative plan
- Investigator's Brochure (IB)
- Clinical protocols
- CMC (chemistry manufacturing and control) data
- Pharmacology & toxicity data
- Previous human experience Additional information



Submitted with the initial IND submission and each subsequent submission to the IND

DEPARTMENT OF HEALTH AND HAMAN SERVICES	Apro Approace CME No. (2010-2014) Specific Date Mar 21, June		
FOOD and DRUG administration	See OMD Statement of Herente		
INVESTIGATIONAL NEW DRUG APPLICATION (IND) (TITLE 21, CODE OF PEDENAL REGULATIONS (CPR) FART 212)	NOTE: No deg may be shipped or cit- transfighter began until an HO for transfighter to in affect (27 CTR) (2, 40).		
 next or showon 	A DATE OF DEMODOR		
 KOPETI /Korin, Direct Dij, Balt of Di Colli 	4. NEED-CHE-HAMEN (Integration)		
1. WHERE'S MITH, Included and an annual Trans, General, Charlos, Grane	1. NEXMED.Junits argued		
MDG/DB/IL/Creatily Residented			
A PARTY FORCE METSON TO BOOK TO DAME: CAME (and Barrie		
 LET REMOTE OF ALL INTERFACEMENTS AND DRIVE APPLICATIONS OF OW AN OF OW ANY TWO DRIVE READ OF OW ANY INVESTIGATION CONTACT APPLICATION. 	an boy, takin bilan din antigerine antiqueri		
TO WTHE WHUDTON			
 NO submission about he consecutively numbered. The initial NO "Sector number 2000." The next automation is a proportional record. 	shauld de numbered		
	inclusions should be		
"Sold number ANY. The next submitted in a sensitive in the should be numbered "Sold Ramber AN". Robustowed and submitted consecutively is the order is article they are submitted.	intestore should be		
a the second list of he has been done and and			
THE DEBUGGE CONTAILS THE POLITIERS (Data of the speci- THE DEBUGGE CONTAILS (THE SPECIAL OF THE SPECI	ACCPORE TO CLARGE, HOLD		
Not address contract for PSLIDERC (State of the optimized in the second state of	ADPONDETS DURING, ADD BE-LIFETY REPORTS		
The Interesting Contract Tay Poly Date of the American Street Stree	ACCPORE TO CLARGE, HOLD		
THE DEBUGGE CONTAILS THE FOLLOWING CONTAINED AND THE DEBUGGED AND THE DESCRIPTION OF ADDRESS AND ADDRESS	ACCIVITE TO CARGO, HIGH INCLARETY INFORMATION INCLARETY INFORMATION		
Tel: Della Contract Sel Publication (Prior de Parageo) Entra Antibiotication (Prior de Parageo) Records antibiotication (Prior de Parageo) Records antibiotication	ALSPONE TO GARGE, MOD INCLEET INCOME INCLEASE ANY TEXADORY PRODUCT TO A MATERIAL PRODUCT TO A MATERIAL INCLEASE ANY TEXADORY		
	ADDARD TO CARGO, MOD INCLUST: INFORMATION INCLUST: INFORMATION PROJECT TO A VALUE OF TO A VALUE OF TO ADDARD, DAMAGED OF TO ADDARD,		
Tel: Della Contract Sel Publication (Prior de Parageo) Entra Antibiotication (Prior de Parageo) Records antibiotication (Prior de Parageo) Records antibiotication	ADDARD TO CARGO, MOD INCLUST: INFORMATION INCLUST: INFORMATION PROJECT TO A VALUE OF TO A VALUE OF TO ADDARD, DAMAGED OF TO ADDARD,		
	Element to announce to announce to announce to announce to announce the second to announce the second to an announce to announce the second to announce the seco		
	AEGMONE TO GLARGE HILD HELEFETY RECEIPTS PROJECT RECEIPTS PROJE		
	REFORME TO LANCE, HUD RE-LETT RECEIVE In and an article and the Re-Lett RECEIVE In and an article and the Receive at the MERICAN AND AND ADDRESS AND AND AND AND AND AND ADDRESS AND AND AND AND AND AND AND ADDRESS AND AND AND AND AND AND AND AND ADDRESS AND		
	REFORME TO LANCE, HUD RE-LETT RECEIVE In and an article and the Re-Lett RECEIVE In and an article and the Receive at the MERICAN AND AND ADDRESS AND AND AND AND AND AND ADDRESS AND AND AND AND AND AND AND ADDRESS AND AND AND AND AND AND AND AND ADDRESS AND		
	REFORME TO LANCE, HUD RE-LETT RECEIVE In and an article and the Re-Lett RECEIVE In and an article and the Receive at the MERICAN AND AND ADDRESS AND AND AND AND AND AND ADDRESS AND AND AND AND AND AND AND ADDRESS AND AND AND AND AND AND AND AND ADDRESS AND		
	притоне то самор, чаро неското постоя стально констрантиров поста постоя стально то констрантиров стально констрантиров совер водок, попрато за сове сталь)		
	REFORME TO LANCE, HUD RE-LETT RECEIVE In and an article and the Re-Lett RECEIVE In and an article and the Receive at the MERICAN AND AND ADDRESS AND AND AND AND AND AND ADDRESS AND AND AND AND AND AND AND ADDRESS AND AND AND AND AND AND AND AND ADDRESS AND		
	притоне то самор, чаро неското постоя стально констрантиров поста постоя стально то констрантиров стально констрантиров совер водок, попрато за сове сталь)		
	притоне то самор, чаро неското постоя стально констрантиров поста постоя стально то констрантиров стально констрантиров совер водок, попрато за сове сталь)		
	притоне то самор, чаро неското постоя стально констрантиров поста постоя стально то констрантиров стально констрантиров совер водок, попрато за сове сталь)		
	Innov reparent.		

FDA From 1571 page 2

The FDA has 30-days to review the protocol. FDA will not contact sponsor if all is OK to proceed, only if a "hold" is needed.

	owing Remo: (Check a	l that apply!	
45.74			
(Jack)			
and a			
10 Disently			
NJ Zheekinker	ar completed Formics P	0A 1672	
Zhartishid a	companied Promoto PDA	4672	
644,57 CPR 312	Zhaotholdul ur comple	and Pormos PDA	4 1672
	• pr c/m and allowing	ALC: UNK	
e*#			
ACCURATE AND ADDRESS	The state in the second of	or They Th	
			1.04
AND ADDRESS OF TAXABLE ADDRESS O	The contract science	+ DRUMED/TON	
ne not to begin : Ref as institution	of Continue Children and	Ref consider a	and by the MD I B
in for initial and	continuing rooks and	approval of an	ch of the studies in
			a approace regard
	C. SOMPLER OF STOR	OR OR SPONSOR	LATIONS BY
	April april 1 and 1		
	AN ADDRESS AND ADDRESS		0.04%
dute for rationing the l	Automation for	And the to be and the	other the harder callender
		34 (\$10.70)	at order or grown or
Andrew Pare		d standte at	and the segment the stands
	A U J J Land J L M U J L L M U J L L L L L L L L L L L L L L L L L L		

Conducting Clinical Trials

- Selecting qualified investigators and monitors
- Informing Investigators
- Reviewing ongoing studies
- Record keeping and record retention
- Ensuring the return or disposition of unused investigational drug supplies

Investigator Selection

- Assess qualification of PI and Subinvestigators
 - Qualified by training & experience
 - Ability to supervise administration of product
- Investigational Product shipped to them
 Assess site (physical plant capabilities).
- Examples:
- Is there adequate pharmacy space for drug storage?
- Are there SOPs for freezer alarms?





Review Ongoing Investigations...

- Investigator compliance is conducting the study in compliance, with the protocol, with the Federal Regulations, and with GCP?
- Is there unreasonable & significant risk to the study subjects?
- Monitor clinical trial conduct



Medical Monitor - individual responsible for the development and oversight of all clinical trials in a portfolio of study agents

...Review of Ongoing Investigations...

Review and evaluate - Safety and effectiveness data



- Provide FDA
 - Annual reports
 - Summary of accrual statistics, safety, toxicity and efficacy data, as well as ongoing nonclinical and manufacturing progress

Potential Actions for Noncompliance

- Secure compliance OR
 - Stop product shipments to the investigator
- Terminate the investigator's participation in the study
- Secure return or disposal of investigational product

Actions for Unreasonable and Significant Risk



- Stop clinical trial: permanent vs. temporary
- Notify the FDA, all IRBs, all investigators of the risk(s)
- Assure the disposition of all outstanding product or resume trial with amendment
- Provide FDA full report on actions taken

Monitoring of Clinical Trials...

- Monitoring function may be • performed by:
 - The sponsor
 - Contract staff





...Monitoring of Clinical **Trials**

- Sponsor must have written monitoring procedures (SOPs) to assure the quality of the study and ensure that each person involved carries out their duties
- SOPs should include:
 - How often will visits occur
 - Who will attend
 - What will be reviewed
 - How will problems be resolved - Communication flow

Record Retention Requirements

- (21 CFR 312.57 and 21 CFR 312.62) Applies to investigational drug records, investigator financial interest records, and patient case histories (medical record and case report forms)
- Retain records and reports for 2 years after a marketing application is approved for the drug
- If NDA application is not approved, retain records and reports until 2 years after shipment and delivery of the drug for investigational use is discontinued and the FDA has been so notified

Disposition of Unused Drug

 Sponsor must ensure the return or destruction of all unused supplies of drug from each investigator



FDA Review of NDA or BLA

- FDA's approval is based on preclinical, manufacturing & clinical data in the NDA or BLA
 - Good Laboratory Practice (GLP)
 - Good Manufacturing Practice (GMP)
 - Good Clinical Practice (GCP)

Resources

- Code of Federal Regulations, Title 45 Part 46: Protection of Human Subjects
- Food and Drugs: Title 21

 21 CFR 312: IND Application
 21 CFR 314: NDA application
- Guidelines for Good Clinical Practice. International Conference on Harmonisation (ICH)

